Market Overview:
The global hematology drugs market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of blood disorders, rising geriatric population, and growing demand for hematology drugs in emerging markets. The global hematology drugs market is segmented on the basis of type into over-the-counter (OTC) and prescription drugs. The OTC segment is expected to grow at a higher CAGR than the prescription drug segment during the forecast period. This can be attributed to the increasing preference for self-medication and growing awareness about available treatment options among consumers worldwide. On the basis of application, the global hematology drugs market is divided into hospital pharmacies, retail pharmacies, and other applications such as research institutes and contract manufacturing organizations (CMOs). The hospital pharmacy segment accounted for a major share of this market in 2017 owing to increased spending by hospitals on medications for patients suffering from blood disorders or cancer. However, with rising healthcare expenditure by consumers worldwide, especially in developing countries, retail pharmacies are expected to witness faster growth during the forecast period.
Product Definition:
Hematology drugs are used to treat various blood conditions including anemia, leukemia, and lymphoma. These drugs can be used to improve the patient's quality of life by improving their red blood cell count or preventing the spread of cancerous cells.
OTC:
OTC stands for Over-the-Counter. OTC drugs are those that can be used without a doctor's prescription. Most of the time, these medications are available in tablet or capsule form and can be purchased from any pharmacy without any medical training. Some examples of OTC drugs include cough syrups, sore throat preparations, laxatives and stool softeners among others.
Rx Drugs:
Rx drugs are those medications which are prescribed by doctors to patients as first-line treatment for a disease or condition. Hematology drugs can be used in the treatment of blood disorders such as anemia, leukemia, and thalassemia.
Rx Drugs market is expected to grow at a CAGR of XX% over the forecast period owing to increasing prevalence of chronic diseases such as cancer, diabetes.
Application Insights:
Based on the application, the global hematology drugs market is segmented into hospital, drug store and others. The other applications include clinics and home care settings. Drug stores are anticipated to be the fastest-growing segment owing to increasing awareness about availability of low-cost medicines coupled with rising incidences of blood disorders.
Hospital is expected to be the largest application segment due largely to factors such as an increase in prevalence of diseases requiring treatment with hematology drugs coupled with a rise in government funding for improving healthcare facilities at hospitals level across countries such as India, China Japan etc. Moreover, growing investments by companies for developing advanced diagnostics & therapeutics solutions will further boost product demand over forecast period.
Regional Analysis:
North America dominated the global hematology drugs market in 2017. The presence of key players, favorable reimbursement scenario, and high adoption rate for new therapies are some of the factors responsible for its large share. In addition, increasing incidence of blood disorders is also expected to drive growth during the forecast period. For instance, according to a study published by National Institutes of Health (NIH), around 33 million people in U.S have been diagnosed with at least one blood disorder or condition and about 7 million people have been diagnosed with two or more conditions simultaneously affecting multiple systems at once (CIMT).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising healthcare expenditure levels coupled with growing patient awareness regarding early diagnosis & treatment options for various diseases especially cancer & autoimmune disorders among other chronic diseases such as cardiovascular disease & diabetes which are further fueling market demand across this region.
Growth Factors:
- Increasing incidence of blood disorders and cancer
- Growing demand for targeted therapies
- Rising awareness about hematology drugs and their benefits
- Technological advancements in the field of hematology drugs development 5. Availability of government funding for research and development in the field of hematology
Scope Of The Report
Report Attributes
Report Details
Report Title
Hematology Drugs Market Research Report
By Type
OTC, Rx Drugs
By Application
Hospital, Drugs Store, Other
By Companies
Celgene, Pfizer, Roche, Sanof, Bristol-Myers Squibb, AbbVie, Novartis, GSK, Johnson & Johnson, Takeda, Celgene
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
215
Number of Tables & Figures
151
Customization Available
Yes, the report can be customized as per your need.
Global Hematology Drugs Market Report Segments:
The global Hematology Drugs market is segmented on the basis of:
Types
OTC, Rx Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drugs Store, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celgene
- Pfizer
- Roche
- Sanof
- Bristol-Myers Squibb
- AbbVie
- Novartis
- GSK
- Johnson & Johnson
- Takeda
- Celgene
Highlights of The Hematology Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- OTC
- Rx Drugs
- By Application:
- Hospital
- Drugs Store
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hematology Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hematology drugs are medications used to treat blood disorders.
Some of the major companies in the hematology drugs market are Celgene, Pfizer, Roche, Sanof, Bristol-Myers Squibb, AbbVie, Novartis, GSK, Johnson & Johnson, Takeda, Celgene.
The hematology drugs market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hematology Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hematology Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hematology Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hematology Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hematology Drugs Market Size & Forecast, 2020-2028
4.5.1 Hematology Drugs Market Size and Y-o-Y Growth
4.5.2 Hematology Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 OTC
5.2.2 Rx Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drugs Store
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hematology Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hematology Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 OTC
9.6.2 Rx Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drugs Store
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 OTC
10.6.2 Rx Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drugs Store
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 OTC
11.6.2 Rx Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drugs Store
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 OTC
12.6.2 Rx Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drugs Store
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 OTC
13.6.2 Rx Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drugs Store
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hematology Drugs Market: Competitive Dashboard
14.2 Global Hematology Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Celgene
14.3.2 Pfizer
14.3.3 Roche
14.3.4 Sanof
14.3.5 Bristol-Myers Squibb
14.3.6 AbbVie
14.3.7 Novartis
14.3.8 GSK
14.3.9 Johnson & Johnson
14.3.10 Takeda
14.3.11 Celgene
